Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals

ABSTRACT The COVID-19 pandemic has emphasized the importance and need for accessible safe, effective, and versatile vaccine platforms. While approved SARS-CoV-2 vaccines have been instrumental in saving lives and reducing healthcare and economic burdens, the induction of mucosal immunity remains an...

Descripción completa

Detalles Bibliográficos

Autores principales:	Najwa D. Aljehani, Levi Tamming, Muhammad Yasir Khan, Rwaa H. Abdulal, Mohamed A. Alfaleh, Aishah Ghazwani, Asalah Helal, Reem M. Alsulaiman, Mohammad A. Sanki, Khalid Alluhaybi, Farah Ayman Sukareh, Rahaf H. Alharbi, Faris H. Alyami, M-Zaki ElAssouli, Salima Shebbo, Wesam H. Abdulaal, Abdullah Algaissi, Ahmad Bakur Mahmoud, Mohammad Basabrain, Diana Duque, Jegarubee Bavananthasivam, Wangxue Chen, Lisheng Wang, Simon Sauve, Turki S. Abujamel, Tarfa Altorki, Rowa Alhabbab, Anh Tran, Xuguang Li, Anwar M. Hashem
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	American Society for Microbiology 2025-01-01
Colección:	mBio
Materias:	vaccine SARS-CoV-2 mucosal vaccines adenoviruses
Acceso en línea:	https://journals.asm.org/doi/10.1128/mbio.02170-24
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!